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EXPLORATION OF NON-SPECIFIC PEPTIDE INHIBITORS OF AMYLIN
AGGREGATION IN TYPE-2 DIABETES
BY: Hector Figueroa

Abstract
Polypeptide aggregation is seen in a variety of diseases (termed amyloidoses) but remains
poorly understood. This study uses the polypeptide amylin to investigate how nonspecific interactions between peptides can inhibit aggregation. A set of 5 heptapeptides
was assessed for its ability to impact amylin-induced membrane damage and aggregation.
Solvent effects precluded accurate assessment of the impact on membrane damage;
however a method of subtracting out the solvent effect is offered. The two most
hydrophobic compounds showed the ability to substantially slow amy lin aggregation,
while those compounds canying charged side chains tended to increase the rate of
aggregation. Only one compound showed a concentration-dependent effect, which is
offered as evidence for specific interactions. This study demonstrates that even random
peptide sequences can have a significant impact on the behavior of an aggregating
species, via specific and nonspecific associations.

Introduction
Protein aggregation is a widespread but poorly understood phenomenon that occurs in
diseases ranging from Alzheimer's, Mad Cow, and Parkinson's to Type-2 Diabetes [for
general reviews on amyloid formation, see ref. 1-3]. In each of these diseases, a unique
polypeptide chain exists which undergoes a transition from a soluble state-usually
considered devoid ofwell-defmed secondary structure--to a P-sheet rich conformer
capable of self-assembling into aggregates. Interestingly, there is little or no sequence
homology among these aggregate-competent polypeptides, despite the structural
similarities of the mature fibrils they form [2]. The relationship between the aggregation
of the polypeptide and the pathogenesis of the disease is unclear, and may be different for
different conditions. However, the presence and deposition of these structurally similar
aggregates, termed amyloid plaques, over the course of the development of these diseases
has led researchers to call these conditions amyloidoses.
In the case ofType-2 Diabetes, the aggregating polypeptide is known as amy lin or
human islet amyloid polypeptide (hiAPP). Amylin is normally stored alongside and
secreted with insulin from pancreatic P-cells, and is thought to be involved in blood
glucose homeostasis [4]. The polypeptide is a 37-residue chain, which contains three
distinct, but somewhat overlapping regions capable of forming amyloid fibrils (8-20, 2029, and 30-37) [5-9]. In vitro, full-length amy lin forms fibrils at concentrations as low as
5 11M [4,10,11], whereas in vivo the polypeptide remains soluble despite being stored at
concentrations estimated at 800 11M [11,12], suggesting that the body has a successful
method by which it prevents amyl in aggregation.
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In addition to aggregating, amylin has also been shown to possess cytotoxic properties
[2, 13-15], thus providing a direct conceptual link explaining how it may participate in the
development ofType-2 Diabetes. Counter-intuitively, however, it is not the mature
aggregates of amylin which damage cells, but rather the oligomer states. This
observation, along with other research, has led many to suggest that it is the aggregation
process itself that damages cells, not the mature fibrils [13-16]. A possible mechanism for
the observed cytotoxicity is that amylin may form pores or channels in cell membranes
[14].
One model being developed suggests that amylin monomers form an a-helical
intermediate that inserts into lipid bilayers prior to aggregation [ 17, 18]. These
intermediates may then cluster together within the membrane prior to transitioning into a
~-sheet 1·ich

structure, which dissociates from the membrane to form the mature

aggregate. In this model, while insetted within the membrane the amylin molecules form
pore structures that allow cell contents to leak out. In fact, it is well established that
amylin aggregation is catalyzed in the presence oflipids [19], which is consistent with a
model in which a membrane-bound intermediate is present on the pathway to
aggregation.
One natural question arising from research on amylin is how the bodies of healthy
individuals prevent amylin aggregation and cell damage. Insulin is the most likely
molecular mechanism by which an organism may regulate amy lin behavior [4,10,20],
though larger scale metabolic regulation is also a potential candidate-and, in fact, the
two are not mutually exclusive ideas. Research has shown that the 10-19 region of the
insulin B-chain binds amylin most strongly [20,21]. Because of this, our lab previously
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synthesized different length fragments of this region of the B-chain in order to determine
the shortest sequence still capable of inhibiting amylin aggregation and membrane
damage [22]. While peptide-based drugs are difficult to deliver to patients, understanding
the underlying molecular mechanisms by which insulin inhibits amylin aggregation is a
frrst step toward the rational design of a potential treatment for Type-2 Diabetes.
Fragments of the 10-19 region of the insulin B-chain were, indeed, capable of slowing
aggregation and decreasing membrane damage at sufficiently high concentrations;
however none of our compounds showed the full effect of insulin, and at lower
concentrations the compounds demonstrated various effects, including increasing the rate
of aggregation in some cases [22]. Consistent with the model in which the
oligomerization of amylin is responsible for membrane damage in cells, those compounds
we synthesized which slowed aggregation to the greatest extent simultaneously showed
the greatest amount of membrane damage. It is worth noting that insulin itself does not
show this effect, and is capable of slowing aggregation without damaging the membrane.
How this is accomplished remains unclear.
Because of the variety of effects witnessed with the insulin fragments we synthesized, a
question of specificity was raised: to what extent will the presence of any compound in
solution with an aggregating species impact aggregation kinetics and membrane damage?
In the field of chemical biology, which is responsible for much of the current drug design

and research in modern medicine, non-specific effects of small molecules are well
established. Research by McGovern and others has shown that high-throughput screening
(HTS) produces a multitude offalse-positives from compounds that show non-specific
reactions with numerous drug target candidates [23-26]. Interestingly, these small-
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molecules may produce false-positives by forming small aggregates capable of trapping
or non-specifically binding to drug target candidates [23-26].
Our results with different length fragments of the insulin B-chain, as well as knowledge
from the field of chemical biology, led to the design of the project presented herein,
whose aim is to explore whether or not amylin aggregation and the associated membrane
damage can be impacted non-specifically by the presence of other peptide compounds in
solution. To begin addressing this, we have designed and synthesized a series of five
peptide compounds, called the NS series (Non-.S_pecific series), which explore a small
region of sequence space. These compounds are assessed here for their impact on amylin
aggregation and amylin-induced membrane damage.
Table 1. NS peptide compounds assayed for their effect
on amylin aggregation and membrane damage.
Peptide

Sequence

Molecular
Formula

Molar

Table 1 shows the sequence of
each compound in the NS series.
NSx5 is a modified version of the

NSx5

YAFDVVG

C37Hs2NsOro

768.87

NSx6

YFSPSFY

C41Hs6NsOu

909.01

NSx7

YFKPKFY

Cs3H7oN1o09

991.20

NSx8

YAYPYAY

C47Hs6NsOr1

909.01

NSx9

YFEPEFY

Cs1H6oNs013

993.08

neuropeptide Deltorphin-1, which
is unrelated to the other sequences
and has no known involvement
with amylin in the human body-

thus, this peptide may be thought of as a 'random' sequence. The remaining compounds,
NSx6- NSx9, are symmetrical heptapeptides of increasing hydrophobicity. The molecules
are symmetrical about a proline residue, and this residue serves to prevent aggregation by
opposing formation of P-sheets [27], and we predict that the symmetry and restricted
conformational freedom should minimize the nature and type of interactions possible
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between amy lin and each compound'. Constructing a non-specific inhibitor of amylin
aggregation and membrane damage can provide a control compound by which the
efficacy of future potential inhibitors may be assessed.

Results & Discussion
Electrospray Ionization-Mass Spectrometry Experiment
Figure 1 below shows the results of an electro spray ionization mass spectrometry
experiment conducted on the NS series of peptides assayed here, using acidic methanol as
solvent. Refer to Table 1 in the introduction for the predicted molecular weights and
sequences of each compound. Three of the peptides synthesized, NSx6, -8, and -9, have
spectra which match the predicted mass. The other two compounds, NSx5 and -7 show
spectra with an M+ 1 peak that is 6 mass units higher than expected. It is difficult to find a
justification for this discrepancy. The most likely cause is a miscoupling during
synthesis; however none of the amino acids common between NSx5 and NSx7 are not
also present in the other pep tides, and none of the amino acids within the sequences differ
by 6 mass units.
Oligomerization of peptides during MS experiments has been observed [28]. A trimer
of peptides surrounding a water molecule would produce a peak that is 6 units higher
than predicted, however this scenario is admittedly far-fetched, and the separation of
isotope peaks by 1 unit suggests that the peaks arc, in fact, M+ 1. The combination of a
sodium adduct followed by loss of an OH- group would also produce peaks that are 6
units larger than anticipated. Another avenue worth investigating is whether or not

• Symmetry here refers only to symmetry in the primary sequence. The chirality of each residue, the 'bend' of the
proline side chain, and the directionality of the peptide bond generally preclude the synthesis of a truly symmetrical
peptide.
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incomplete cleavage of one of the protecting groups on the side chains of either peptide
during synthesis would explain the ESI results.
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Compare MW values to the predicted values given in Table I in the introduction.
Compounds NSx6, -8, and -9 show the predicted mass. Compounds NSxS, and -7 show
an M+ I peak that is 6 mass units higher than predicted. The explanation for this is
unclear, however likely possibilities include a miscoupling during synthesis, or failure of
a protecting group to be cleaved during purification. Alternatively, oligomer states could
explain the observed peak, but these are difficult to justify. Since the spectra are
extremely clean (i.e. there is no sign of significant impurity) the compounds were carried
through the assay process with the assnmption that the modification responsible for the
deviation from the predicted molecular mass would not be significant. This study
attempts to explore whether or not amylin aggregation can be impacted non-specifically
by other peptide molecules in solution, and so the exact stmcture of the compounds can
be somewhat ambiguous without hindering the integrity of the results. Further
experiments will be conducted, regardless, to attempt to figure out the cause of the
discrepancy between the observed and calcnlated masses.
It is worth noting that all of the spectra are extremely 'clean,' in other words there is no

suggestion of any impurity in the samples. This shows that in each case some peptide was
successfully synthesized and purified, and the spectrometry results are not likely the
result of an impurity or side reaction during the synthetic process. Since the study
presented here attempts to examine whether or not amylin aggregation can be influenced
non-specifically by the presence of other peptide molecules in solution, even slight
alterations in the predicted structure ofNSxS and NSx7 do not impact the integrity of the
results since they can simply serve to sample a larger portion of sequence space.
Therefore, all of the NS compounds were carried through the entire assay process despite
the discrepancies observed in the ESI experiments. We are continuing to explore avenues
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by which we may resolve the disagreement in molecular weights, including NMR and
proteolytic experiments.

Dye Leakage Assay
Because amy lin is known to compromise cell membranes such that cell contents leak
out, we can use lipid vesicles (liposomes) containing dye to measure the extent of
membrane damage [16-18]. As amylin molecules form pores in the liposomes, the dye
encapsulated within is allowed to escape, which we can monitor as an increase in
fluorescence compared to control reactions without amylin. In this study, we use
detergent-treated vesicles as a positive, 100% control showing maximal fluorescence and
vesicles in buffer as a measure of the baseline (0%) fluorescence in the absence of
amylin. The extent of amylin-induced membrane damage is calculated as the percent
emission above baseline, compared to the detergent-treated control. To test what effect
the NS peptides have on membrane damage, the amylin is fixed at I 0 [!M and assayed
against a range ofNS peptide concentrations from 2 to 100 [!M.
Figure 2 shows the percent change in dye leakage compared to an amylin sample run
concurrently for each of the NS compounds synthesized. Negative values indicate
reduced membrane damage while positive values mean greater dye leakage was
observed. All assays were performed in triplicate, and average values are reported. The
variation in fluorescence readings inherent to the instrument is small (2 fluorescence units
or less for all trials); the variation among individual samples within a single assay is
-10% in all cases (error bars).
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Figure 2. Dye leakage assay results for each of the NS compounds. In this assay,
membrane damage is measured as the increase in fluorescence (compared to a baseline

control containing only vesicles and buffer) caused by leakage of carboxyfluorescein dye
from model Iiposomes in the presence of amylin. A detergent-treated buffered vesicle
solution serves as a 100% leakage control (maximal fluorescence). The average value of
triplicate runs are reported as percent changes compared to the amount of dye leakage
observed with a 10 [!M sample of amylin run concunently. The amount ofNS peptide
added was varied from 2 to I 00 [!M (0.2x amylin concentration up to I O.Ox amylin
concentration). All effects observed are concentration-dependent (Figure 3). Negative
values indicate a decrease in membrane damage, while positive values show an increase.
In all cases, the amount of membrane damage was observed to increase significantly at

higher concentrations. This startling effect prompted further investigation, which has
suggested the results of this assay are due to solvent effects as discussed in the text. Enor
bars represent an~ 10% variation in reactions in all cases.

The results of our dye leakage assay are surprising. In all cases, a significant increase in
membrane damage was observed at higher concentrations ofNS peptide (above
equimolar for all compmmds). This implies that all of the peptides synthesized here either
enhance the effect of amylin or are themselves capable of damaging membranes. Figure 3
shows a plot of the percent change in dye leakage as a function of NS concentration.
Reasonable linear fits are obtained, suggesting that the effects are concentrationdependent. Additional dye leakage assays with each NS peptide showed that membrane
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damage was, in fact, observed with the NS series alone-i.e. even in the absence of
amylin [data not shown].
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Fignre 3. Concentration-dependence of the dye leakage assay results, presented in Figure
2. The significant increase in dye leakage observed in all cases at higher concentrations,
coupled with the near-perfect linearity of the effect prompted further investigation which

suggests that the results seen here are due primarily to solvent effects, as discussed in the
text.
The fact that each compound shows such a striking increase in membrane damage at
higher concentrations, and yet shows varying effects at equimolar and substoichiometric
concentrations prompted further investigation of the dye leakage assay results. Coupled
with the near-perfect linearity of the effects (see Figure 3), it was suggested that the
solvent used to dissolve the peptides for the dye leakage assay (DMSO) might be
responsible for the membrane damage. In order to test this directly, a control dye leakage
assay was performed on DMSO and methanol, each in the presence and absence of dyecontaining liposomes. Figure 4 shows the results of this control run. Volumes ofDMSO
and methanol were chosen based on the volumes ofNS peptide stock solution that had
been used for the dye leakage assays (NS peptides were originally dissolved in pure
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DMSO, see Materials and Methods section). Unlike Figure 2, the values reported are raw
emission values (528 nm), not percent changes, in order to better illustrate the effect. In
the absence of vesicles, neither DMSO nor methanol shows any fluorescence. However,
once vesicles are added, a large increase in fluorescence is observed, indicating that both
organic solvents may be capable of damaging lipid membranes. This further suggests that
the results depicted in Figure 2 with each of the NS compounds may actually be due to
solvent effects, and not a result of interactions between the peptides and amylin.
60.0
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Figure 4. Control dye leakage assay to determine if organic solvents DMSO or methanol
(MeOH) can incnr membrane damage. Positive control (+) is a detergent-treated solution
with dye-containing vesicles, while the negative(-) control is dye-containing vesicles in
buffer. The volume (in f.LL) of solvent assayed is indicated by a numerical designation,
and the volumes were chosen to reflect the volume ofNS peptide solution assayed in the
trial dye leakage assays reported in Figure 2. In the absence of vesicles, neither DMSO
nor MeOH show any significant fluorescence (D-# and Me-# columns). Once vesicles are
added, however, a striking increase in fluorescence is seen (DV-#, MeV-# columns). This
effect is concentration-dependent (data not shown), and suggests that the results of onr
dye leakage assays on the NS compounds may be due to solvent effects.

In order to determine whether or not the DMSO solvent was in fact responsible for the

observed increases in dye leakage, and whether or not this effect could be accounted for,
we assayed the NSx5 compound in a different manner. The results are given in Figure 5.
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One aliquot ofNSx5 was dissolved in pure DMSO, while another was dissolved in 50 f!L
ofDMSO and then diluted with sodium phosphate buffer up to 2620

flL total volume (the

same volume as that of the sample dissolved in pure DMSO, see Materials and Methods
section). These two solutions ofNSx5 were assayed alone as well as against 10 f!M
amylin.
Concurrently, a series ofDMSO solutions was assayed in order to build a 'standard
curve' to measure the increase in emission over baseline as a function of the volume of
DMSO added. This standard curve provided only a general estimation of the exact
volume dependence of the emission change, however, and is not shown here. From the
curve, we subtracted out the estimated effect of the DMSO solvent for both the NSx5
solution dissolved in pure DMSO as well as the solution diluted with buffer.
Looking at Figure 5, it can be seen that simply diluting the peptide with buffer is
sufficient to remove the enhanced dye leakage effect seen in the pure DMSO solution.
Subtracting out the effect of DMSO from both solutions removes virtually any observed
increase in dye leakage, which is consistent with the hypothesis that the results depicted
in Figure 2 are due solely to solvent effects. Additionally, it is worth noting that diluting
the peptide solution with buffer or subtracting out the effect ofDMSO abolished any
concentration-dependence [data not shown]. It also appears that NSx5 may actually
decrease the amount of membrane damage seen to a small extent. At this point, we
cannot explicitly generalize these findings to all of the compounds in the NS series until
we have finished re-assaying them in dilute buffer or a different solvent system.
However, it seems likely that all of the compounds will display significantly different
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effects on amylin-induced membrane damage once the effect ofDMSO has been
accounted for.
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Figure 5. An attempt to account for the observed effect of DMSO on the dye leakage

assay using the NSx5 compound. Two solutions of the NSx5 peptide were prepared, one
in pure DMSO, the other in dilute DMSO. This alone resulted in a significant change in
the observed effect on dye leakage; in fact, the NSx5 peptide does not seem to increase
membrane damage at all when in dilute DMSO. Assayed concurrent with these two
solutions was a series ofDMSO controls with dye-containing vesicles in order to build a
standard curve for the increase in fluorescence over baseline caused by DMSO. Based on
the values obtained, the results of the Pure DMSO and Dilute DMSO percentages were
adjusted to subtract out the effect of solvent. Perfmming this operation results in both
NSx5 solutions showing little if any increase in dye leakage, consistent with the idea that
the original results were due only to solvent effects.

Thioflavin T Aggregation Assay
The commercially available dye, thioflavin T, preferentially binds to the

~-sheet

structure of amyloid fibrils. When it does so, it shows enhanced fluorescence with
excitation and emission maxima at around 450 and 480 nm, respectively [29]. The
binding mode of the dye to amyloid fibrils is not well characterized. However, as fibrils
form, more and more dye binds to the growing aggregates, producing an increase in
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fluorescence that can be monitored over time. In the case of amylin aggregation, a typical
thioflavin T assay will show a lag phase, in which aggregation nucleation centers are
forming, followed by a sharp increase in fluorescence as fibers elongate. This phase is
short because of the cooperative nature of the aggregation process. After this, once the
maximum number of fibers has fmmed, a plateau phase occurs at some maximal
fluorescence value. The overall shape of the graph should be sigmoidal, which is typical
of cooperative processes. Figure 6 shows a representative plot of a typical amylin
thioflavin T assay under our experimental conditions. The reader should note that the
analysis performed on the graph is similar to that used for enzyme kinetics.
Typically, the value of primary interest is the time at which 50% of the amylin is in the
aggregated form (t 112). This is conceptually similar to the Michaelis-Menton constant, or
the K, of inhibitor studies. In the presence of an inhibitor of aggregation, the t 112 should
increase and the graph should shift to the right (since a greater amount of time will be
needed for half of the amylin to aggregate). The converse is also true, and is often seen: if
a compound accelerates aggregation, a shift to the left will be seen and the t 112 will
decrease. In this study, we have scaled all plots as a percent of maximal fluorescence,
which allows one to read the t 112 value directly from the graph by simply scanning along
the line, y= 50%. It is worth noting that this assay is performed in the presence of model
liposomes (without dye) in order to catalyze the aggregation process as well as to mimic
the in vivo environment in which amy lin aggregates in Type-2 Diabetes.
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Figure 6. Representative thioflavin T profile for amyl in alone under the assay conditions
used in this study. A sigmoidal curve is indicative of cooperative amyloid formation. A
clear lag time is visible, during which aggregate nucleation centers are forming. This is
followed by a sharp increase in fluorescence as fibers elongate cooperatively. Finally, the
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tl/2 directly fi·om the graph (in this case, just under 4000 sec). This value represents the
time at which 50% of the amyl in has formed fibers, and is the value typically used to
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Figure 7 shows the results of the thioflavin T assay performed with 10 f!M amylin in
the presence of varied concentration of each NS compound (range: 2 to 100

IJM, the same

concentrations used for the dye leakage assay). NS and amylin stock solutions were
prepared using the minimal amount ofDMSO needed to dissolve the peptide and diluted
with buffer. Control runs with each NS compound at all concentrations, DMSO in the
presence and absence of vesicles, and buffered dye alone showed that no assay
component other than amylin produces any fluorescence above baseline (0-2 fluorescence
units). Within each assay, a variation of -3% was seen for all reactions in all cases (error
bars in Figure 8).
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Figure 7. Thioflavin T results for 10 )1M amylin assayed against increasing amonot of
NS componod (range: 2 to 100 )1M, legend indicates the ratio ofNS peptide: amylin).
The color codes across all plots match, and the dark blue line represents amylin alone,
without NS peptide. All plots have been scaled as percent of the maximal emission to
allow ease of comparison. Compared to amy lin by itself,. a shift to the right indicates
slower fiber formation, while a shift to the left indicates an increased rate of aggregation.
A variation of -3% was seen for all reactions. NSx6 slows aggregation considerably,
such that at its maximal concentration a plateau phase was not seen until near the end of
the assay. The effect ofNSx6 seems concentration dependent (Figure 9). NSx8 also
slows amylin aggregation, however the effect does not appear to correlate with
concentration or molar ratio, perhaps indicating a non-specific effect. Of the remaining

compounds, NSxS and NSx9 both increase the rate of aggregation. NSx7 shows varied
effects, sometimes increasing, sometimes slowing the aggregation rate. These results
underscore the fact that even a random peptide in solution with amylin can have a
substantial impact on the rate of aggregation observed, and that future studies must take
care to account for non-specific effects their pep tides might exert.

The results of Figure 7 show that even a 'random' peptide in solution with amylin can
have a substantial effect of aggregation kinetics. NSx6 shows a concentration-dependent
effect in which amylin aggregation is slowed significantly. At the highest concentration
(1 00 f!M NSx6), the lag phase is extended until almost 4 hr 40 min. NSxS also seems
capable of slowing amylin aggregation to a significant extent; however, the effect does
not correlate with concentration, which may indicate a non-specific effect. Of the
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remaining compounds, both NSx5 and NSx9 increase the rate of fibril formation
compared to amylin alone. NSx7 shows varied effects, sometimes increasing and
sometimes decreasing the rate of aggregation. These results do not undermine previous
studies, but rather serve as an example that peptide compounds synthesized without any
particular connection to amylin can still show a profound impact on its behavior. Future
studies with amylin should be aware of this, and a strategy designed to deal with possible
non-specific effects of any potential peptide inhibitors.
Another way of presenting the data in Figure 7 is to compare the t 112 values for each NS
compound. It is important to note that not all compounds were assayed together at the
same time. Therefore, it is not appropriate to compare their tu2 values directly. In
different assays, amylin may show different lag times and slightly different maximal
fluorescence values. This is partly due to the fact that both the thioflavin T dye and the
liposome solutions used to catalyze the reaction must be prepared fresh for each assay.
Slight differences in dye concentration may impact the intensity of the readings. Using
different lipid stock solutions for each assay means that the same vesicle concentration
will not be present for each trial, which can impact the rate of amylin aggregation.
Because of these factors, it is necessary to adjust each t 112 value in order to make them
comparable across assays. This is most readily accomplished by dividing the NS t 112
value by the t 112 of the amy lin sample run at the same time and converting the value to a
percent. This allows one to compare the change in the rate of aggregation incurred by
each NS compound measured against the rate of amylin aggregation alone. Figure 8
presents the t 112 values for all of the NS compounds adjusted in this way. Bars extending
in the positive y-direction indicate a slowing of aggregation, while bars in the negative y-
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direction show an increased rate of aggregation. From this plot, it is easy to see the
substantial effect that the compounds NSx6 and NSx8 have on amylin behavior, as well
as the general trend of the remaining compounds to increase the rate of aggregation.
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Figure 8. Comparison of adjusted tu2 values for each NS compound. The t 112 is obtained
from the graphs shown in Figure 7. By dividing these values by the t112 of the amylin
sample run at the same time and converting to a percent, one obtains a dimensionless

value, which can be compared with other assay results not run at the same time. Positive
values indicate a decrease in the rate of aggregation, while negative values show an

increase in aggregation kinetics. Both NSx6 and NSx8 substantially decrease the rate of
aggregation. Only the effect ofNSx6 seems concentration-dependent. NSx5 and 9 both
increase the rate of aggregation. NSx7 increases the rate of aggregation at all but the
lowest molar ratio; the effect does not appear concentration-dependent. Error bars
represent an ~3% variation in all reactions.

Finally, we checked for concentration dependence with respect to the thioflavin T
results (Figure 9). Only NSx6 seems to exert a concentration-dependent effect. NSx9 may
show a weakly concentration-dependent effect if the regression analysis is nonlinear (data
not shown, R2 = 0.8). The effect of all other compounds is not concentration-dependent.
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We suggest that a concentration independent effect may be an indicator of non-specific
effects.
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Fignre 9. Concentration-dependence of the results of the thioflavin T assays. Only the
effect ofNSx6, which was to significantly slow the rate of amylin aggregation, appears
concentration dependent (R'~ 0.97). All other compounds do not seems to exert
concentration-dependent effects, perhaps indicating that their interactions with amy lin are

non-specific.

Conclusions/ Future Prospects
This study has shown that even a random peptide can have a significant effect on the
behavior of an aggregating species. This underscores the need for understanding the
molecular mechanisms behind protein aggregation as well as taking care to rule out nonspecific effects in future studies dealing with amylin aggregation. It seems likely that the
concentration-dependence seen in the way that NSx6 slows amylin aggregation may
indicate a specific effect. Because of the high sequence similarity between NSx6-9, it is
reasonable to speculate as to why the compounds show such dispamte effects. Of all the
compounds assayed, only NSx8 aud NSx6 do not cany charged side chains (see Table 1,
NSx7 carries two lysines, NSx5 and NSx9 carry a single aspartic acid and two glutamic
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acid residues, respectively), and both of these compounds demonstrated an ability to slow
amylin aggregation.
Hydrophobicity is therefore one logical explanation for the observed effects, since the
symmetric nature of each compound as well as the intervening proline restricts the
conformational freedom of each NS peptide. However, our previous research showed a
correlation between the ability to form salt bridge interactions with amylin and slowing
of its aggregation [22]. It was observed that a glutamic acid residue on potential
inhibitors was able to bind to an arginine residue on amylin. Modeling studies indicated
that the strength of this salt bridge interaction was strongly related to the ability of the
compounds to slow aggregation. We would therefore expect that NSx9 and NSx5 might
be able to slow aggregation by forming an analogous salt bridge association; this does not
appear to be the case, however. Conformational factors may be responsible, but further
experiments are needed to confirm this.
Our lab has also previously correlated increased membrane damage with slowing the
rate ofamylin aggregation [22]. As such, it would be desirable to be able to plot the
change in aggregation kinetics of each of the NS compounds against the change in dye
leakage to see whether or not this trend holds for the series investigated here. However,
due to the solvent effects of the DMSO, we cannot do this until all of the dye leakage
assays have been repeated under different solvent conditions. It is worth noting, however,
that when the effect ofDMSO is subtracted from the dye leakage assay performed on
NSx5, a decrease in membrane damage is seen at all concentrations (compare Figures 2
and 5 with respect to NSx5). Since NSx5 also shows an increase in the rate of
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aggregation at all concentrations (Figures 7 and 8), this suggests that the two observable
behaviors may be correlated in this series of peptides.
Based on this, a prediction about how each of the NS peptides will impact membrane
damage can be made. Both NSx6 and NSx8 slow amylin aggregation, and therefore are
expected to increase the amount of membrane damage. NSx5 and NSx9 increase the rate
of aggregation and so would be predicted to show a decrease in the extent of membrane
damage. NSx7 shows an ability to slow aggregation only at the lowest concentration
assessed here (2 f!M), which predicts that at this concentration an increase in membrane
damage would be seen, while at all others the reverse would be the case.
On the other hand, if a correlation between increased membrane damage and slower
aggregation rates is not observed, this could provide mechanistic details about the
interactions between amylin and each of the NS compounds. Based on the model of
amylin aggregation in which the membrane-bound intermediate is responsible for pore
formation, and thus cell damage, a compound which preferentially binds the soluble form
of amylin-i.e. before it binds to lipid membranes-could, in principle, slow aggregation
without increasing membrane damage. This is not a certainty, but rather a testable
hypothesis for future experiments.
Finally, binding studies should be performed to investigate the molecular interactions
between NSx6, NSx8, and amylin in order to uncover the mechanism by which each is
exerting its effects. In this way, this study also provides two novel lead compounds that
can be tested for potential use as aggregation inhibitors. The discovety of such
compounds through serendipity is one of the historic hallmarks of scientific discovery.
However, it is important to note that the true aim ofthis experiment is to emphasize how
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non-specific interactions between molecules can play a significant role in the results
obtained.

Materials/ Methods

Peptide Synthesis
Samples of full-length human amylin (3905 g/mol; purchased from SynBioSci,
Livermore, CA, or Anaspec, Freemon!, CA) were dissolved in HFIP
(hexafluoroisopropanol), aliquoted in 0.5 mg increments, frozen in dry ice/ acetone and
lyophilized for storage. Regular, protected amino acids were obtained from Bachem
Americas, Inc. (Torrance, CA), Anaspec (Freemont, CA), and Synthetech, Inc. (Albany,
OR). Coupling agents and resins were purchased from Bachem Americas, Inc. and
Midwest Biotech, Inc. (Fishers, IN). Solvents and deprotection agents were obtained
from Fisher Scientific (Pittsburgh, PA) and Sigma-Aldrich Chemical Co. (St. Louis,
MO). Peptides in the series investigated here were synthesized on a PS3 Automated
Peptide Synthesizer from Protein Technologies (Tucson, AZ) using established protocols
for Fmoc (N-a-fluorenylmethyloxycarbonyl) protected amino acids on Rink amide
MHBA resin (p-methylbenzhydrylamine; 0.70 mmole/g) on a 0.1 mmole scale. This resin
yields a C-terminal amide ('carboxamide') upon cleavage.
The deprotection solution for N-terminal amines was 20% piperidine in DMF (N,Ndimethylformamide). The coupling agent for synthesis was HBTU (0-(Benzotriazol-lyl)1,1,3,3-tetramethyluronium hexafluorophosphate) activated with 0.4 M DIEA (N,Ndiisopropylethylamine) in DMF. Deprotection of side chains and cleavage from resin was
performed simultaneously with 11 mL 90% TFA (trifluoroacetic acid)/ 10% scavenger
cocktail (phenol and water) as described previously [16]. Crude peptide product was
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purified by preparative reversed-phase high performance liquid chromatography (RPHPLC) on a Waters (Milford, MA) instrument with a Phenomenex (Tonance, CA)
Jupiter CIS colunm (2.2 x 25.0 em, 10 mL/ min), using a linear gradient of 10%
acetonitrile (0.1% TFA)/ water (0.1% TFA) to 50% acetonitrile (0.1% TFA)/ water (0.1%
TFA). Fractions containing pure peptide were frozen in dry ice/ acetone bath and
lyophilized for storage.

Peptide Analysis
Peptide purity was assessed by analytical RP-HPLC. Peaks were monitored at 280 nm.
All synthesized peptides were 2: 97% pure as analyzed by peak integration. Electrospray
mass spectrometry, courtesy of Dr. Ruth Ann Armitage, was used to determine if peptide
products matches the appropriate molecular weights.

Preparation ofLarge Unilamellar Vesicles (LUVs) Containing Carboxyfluorescein Dye
Lipids were purchased from Avanti Polar Lipids (Alabaster, AL), and
carboxyfluorescein dye from Sigma-Aldrich (St. Louis, MO). Lipid vesicles were created
in order to encapsulate the dye. Disruption of the vesicle membrane causes the dye to
leak into the surr-ounding buffer, providing a straightforward way to measure the amount
of amylin-induced membrane damage. Baseline controls were compared to runs with
added peptide and added detergent (which acted as a positive contml to give 100%
leakage).
The protocols for LUV preparation and the dye leakage assay have been described
previously [16]. Briefly, vesicles were prepared by taking 5 mg of a 7:3 ratio of the lipids
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1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3(phospho-L-serine) (OOPS), respectively, and dissolving it in 2 mL of chloroform. The
chloroform was evaporated by a gaseous nitrogen stream, creating a thin film oflipid on
the side of a test tube, which was then dried in a vacuum desiccator overnight. 500 11L of
30 mM carboxyfluorescein dye in a pH 7.5 sodium phosphate buffer solution was added
to the dried lipid to make multilamellar vesicles (MLVs). This solution was vortexed
thoroughly to mix the components and subsequently frozen using dry ice and acetone and
thawed five times consecutively. The solution was then extruded 21 times through
polycarbonate filters (pore size 200 nm) using a mini-extruder from Avanti Polar Lipids,
fitted with two 1000 11L Hamilton gaslight syringes, producing large unilamellar vesicles
(LUVs). To remove non-encapsulated carboxyfluorescein, the LUV solution was placed
on a Sephadex G50 gel exclusion colunm and the first colored fragment, the separated
dye-containing vesicles, was collected.

Dye Leakage/ Membrane Damage Assay (Carboxyfluorescein Assay)
Peptide stock solutions for the dye leakage assay were prepared as follows. A 0.70 mM
stock solution of amylin was formed by dissolving a single 0.5 mg aliquot in 40 rtL
dimethyl sulfoxide (DMSO) and diluting with 144 rtL sodium phosphate buffer (pH 7.5).
Corresponding 0.70 mM stock solutions of each peptide in the NS series were created by
dissolving 1.83 rtmol of pure, lyophilized peptide in 2620 rtL DMSO.
To a 3 mL test tube containing an appropriate amount of buffer, aliquots of each NS
peptide were added in increasing amounts per sample while amylin was added at a fixed
volume to produce a final concenh·ation of 10 rtM amy!in. Once both peptides were
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added to the test tube, a 20 [!L aliquot of dye-containing vesicle solution was added. The
total assay volume was 1.5 mL. NS compound concentrations ranged from 0 to 100 [!M,
allowing us to look at their impact on amylin-induced membrane damage over a large
concentration range and compare that to what occurs with amylin itself. Control runs with
only NS peptide and vesicles were run concunent with test reactions to investigate
whether or not our novel peptides are themselves capable of damaging membranes.
Once all assay components were added, the test tubes were mixed by inversion, and
300 f!L from each tube was transfened to a well in a 96 well plate, which was inserted
into a FLx 800 Fluorescence Microplate Reader (BioTek Instruments, Winooski, VT)
with KC4 software (filters set to 485 nm excitation, 20 nm bandwidth, 528 nm emission,
20 nm bandwidth). A time-course fluorescence spectrum was taken over 180 minutes.
The control used to determine 100% leakage was detergent, 80 [!L Triton X (20% v/v in
buffer), which induced the release of any remaining dye from vesicles, resulting in the
highest possible fluorescence. Dye leakage was reported by the equation:
Percentage of dye leakage = (F - F baseline)/(F detergent- Fbascline)
where Fboseline was the fluorescence of the LUVs in the absence of peptide (buffer only).
The spectra were saved and compiled in Microsoft Excel. Since little time dependence
was observed, the percentage of dye leakage was averaged over the three hour time
period. All assays were run in triplicate and average values are reported.

Thiojlavin T (ThT) Assay
Thioflavin Twas purchased from Sigma-Aldrich (St. Louis, MO). The ThT assay has
been described previously [13,16]. Briefly, vesicles of7:3 DOPC/DOPS were prepared as
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described above, except that carboxyfluorescein dye was absent. The presence of lipid
vesicles in this assay serves to catalyze amylin fiber formation and more closely mimic
the in vivo environment in which amylin is thought to aggregate.
It was necessary to adjust the total assay volume to 1.3 mL for our series in order to
minimize the amount of amylin consumed. Both amylin and each NS peptide were used
from 1.28 mM stock solutions. The amylin stock was prepared by dissolving a single 0.5
mg aliquot in 40 f!L DMSO and 60 f!L of sodium phosphate buffer (pH 7.5). NS peptide
stocks were created by dissolving 1.96 11mol of each peptide in 100 11L DMSO then
diluting up to 1.5 mL by slow addition of sodium phosphate buffer with mixing to avoid
precipitating the peptide. Only the NSx7 peptide (sequence YFKPKFY) did not dissolve
in 100 f!L DMSO; instead 500 f!L DMSO were needed, diluted with 1000 f!L of buffer.
Each assay reaction was assembled as follows in a 3 mL test tnbe. Increasing amounts
ofNS peptide were added to buffered solutions containing thioflavin T (ThT) dye (fmal
dye concentration: 25 f!M). As with the dye leakage assay, NS peptide concentrations
ranged from 0 to 100 f!M. Subsequently, sufficient amylin was added to each tnbe to
achieve a final, fixed concentration of 10 f!M. Finally, 30 f!L of the vesicle solution
containing LUVs without dye was added to catalyze fiber formation. Each solution was
mixed by inversion, then 300 f!L from each tnbe was transfened to a well in a 96 well
plate, which was inserted into a FLx 800 Fluorescence Microplate Reader (BioTek
Instruments, Winooski, VT) with KC4 software (filters set to 440 nm excitation, 30 nm
bandwidth, 485 nm emission, 20 nm bandwidth). A time-course fluorescence spectrum
was taken over a minimum of 4 hours, 30 minutes. Each assay was run in triplicate. A
sigmoidal increase in fluorescence intensity over time indicated fiber formation. The ty, of

29

each run was calculated from the plot to assess the impact of each peptide on the kinetics
of amylin fiber formation. Controlmns with DMSO, vesicles, and each NS peptide
showed that none of the assay components showed fluorescence under the reaction
conditions used here.
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